Independent Exclusive:

NHS pays millions of pounds more than it needs to for drugs

Many alternatives available for a small fraction of the price

The National Health Service is spending almost £25m a year on supplies of an antidepressant drug despite evidence that it has little clinical advantage over an almost identical medication which costs a fraction of the price.

An investigation by the Bureau of Investigative Journalism (BIJ) for The Independent has raised questions about the only independent study to find evidence that the drug, Cipralex, is clinically more effective than its out-of-patent predecessor, Cipramil. Both have a similar main ingredient but Cipralex costs £14.91, while the older Cipramil is available for just £1.31.

The inquiry sheds light on the lengths to which pharmaceutical companies go to extend the lives of drugs whose patents are about to run out.

Cipralex, or Lexapro, as it is known in the US, is one of the most widely prescribed antidepressants in the world, but has been criticised for being little different from Cipramil, whose patent expired in 2002.

There has only ever been one independent, direct comparative study which suggests that Cipralex is clinically more effective. The Bureau’s investigation has now established connections between an individual working for Lundbeck, the Danish company that makes both Cipralex and Cipramil, and Arbacom, a Russian company that sponsored the independent head to head trial.

That trial helped to make the case for the new drug to clinicians, costing the NHS millions of pounds more in prescription costs. Last year, the health service spent about £3.3m more on Cipralex than on Cipramil, although the older drug was prescribed nine times as often. A paper based on the Arbacom trial, which was published in November 2007 in the medical journal Clinical Therapeutics, acknowledged "Alexander N Postnov and Markus Kornfeld at Arbacom for their help in revising the manuscript". It appears that Mr Kornfeld may have assisted at the same time that he and his wife, Asa, were working for Lundbeck.

The BIJ has seen an email from Mr Kornfeld, dated August 2005, in which he sent a protocol for the trial to a Russian woman, copied to someone called "Alex", with a message listing errors in the protocol. In August 2005, Mr Kornfeld was a Lundbeck consultant and his wife was a senior employee.

Mr Kornfeld's email also forwarded a case-report form. The document's properties appear to show this was created only two days previously, and had been modified by a different Lundbeck employee. Mr and Mrs Kornfeld no longer work at Lundbeck and neither responded to requests for comment. Anders Gersel Pedersen, Lundbeck's executive vice-president for drug development, agreed that Mr Kornfeld was a consultant at the time but said nobody at Lundbeck, to the best of the company's knowledge, had known about the Russian Arbacom trial.

The BIJ was unable to contact anyone from Arbacom, which does not appear to have been named as a sponsor of any published research before or since. The bureau uncovered further connections between Lundbeck and Arbacom. While the Arbacom trial was under way, Lundbeck entered into a research contract for an epilepsy drug with another Russian company.

In 2006 and 2007, when the Cipralex trial was being carried out, Lundbeck negotiated a research contract for an epilepsy treatment, VLB01, with the Russian firm Valexpharm. Documents seen by the bureau attach a value of $2m to the deal. Mr Kornfeld and Alexander Postnov, who were acknowledged in the Clinical Therapeutics paper about the Cipralex trial, were sent the contract. It is not clear who Mr Kornfeld was working for at this time, but Mr Postnov was using his Arbacom email address. Valexpharm appears in some listings at the same address as Arbacom, and Valexpharm appears to have registered Arbacom's telephone numbers. Another employee apart from Mr Postnov appears to have worked for both firms.

A spokeswoman for Sistema, Valexpharm's parent company at the time of the trial, denied that Arbacom was related to Sistema in any way.

However, Valexpharm's current chief executive Alexander Bakhutashvili, a former president of Valexpharm's immediate parent company Binnopharm, described Arbacom as a "partner generic company".

Mr Pedersen insisted that there was "absolutely no linkage" between the epilepsy drug contract and Arbacom's Cipralex trial. He said Arbacom had been trying to prove that Cipralex and Cipramil were identical, with the aim of producing a cheaper version of the former. When the results came out proving the clear superiority of Cipralex, he said, Arbacom offered to sell the data to Lundbeck. "We told them to publish," Mr Pedersen said. The company ended up paying for Arbacom's data, he added, but this was its only involvement in the trial. "Regulators prefer studies done by pharmaceutical companies because they are rigorous," Mr Pedersen said. "There was no reason at all for us to be involved with the Arbacom trial."

But questions remain over whether Cipralex represents good value for money to the NHS. The drug has been cited as an example of "evergreening" – a strategy manufacturers use to extend the life of a drug patent. When a drug is about to go off-patent, which would allow it to be copied and sold in a cheaper generic form, the company slightly alters the chemical make-up of its drug and files a new patent. This version is then protected and sold as a new drug, although it often contains similar ingredients to the old one.

Cipramil's patent expired in 2002, at a time when it accounted for 80 per cent of Lundbeck's revenues. Just before this, Lundbeck released Cipralex on to the market. In an article in the British Medical Journal, a senior cardiologist argued: "When resources are limited, giving one patient an expensive drug with no added value when cheaper alternatives exist stops other patients getting treatments they need."

Lundbeck rejected suggestions of "evergreening" in the case of Cipramil and Cipralex. "That is simply not the case," said Mr Pedersen.

A spokeswoman from the Department of Health said: “We are modernising the NHS so we can give patients better access to the medicines they need. That is why we are changing the way drugs are priced to ensure they offer value for money.

“Doctors should be able to focus on what matters most - achieving the best health outcomes for their patient. Value-based pricing will ensure that the price the NHS pays for medicines is based on an assessment of their value, looking at the benefits for the patient, unmet need, therapeutic innovation and benefit to society as a whole.”

www.thebureauinvestigates.com

News
Alan Bennett criticised the lack of fairness in British society encapsulated by the private school system
peopleBut he does like Stewart Lee
Sport
David Moyes and Louis van Gaal
football
Arts and Entertainment
Sheridan Smith as Cilla Black and Ed Stoppard as her manager Brian Epstein
tvCilla Episode 2 review: Grit under the glamour in part two of biopic series starring Sheridan Smith
News
i100
PROMOTED VIDEO
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
Life and Style
Vote with your wallet: the app can help shoppers feel more informed about items on sale
lifeNew app reveals political leanings of food companies
Arts and Entertainment
The cover of Dark Side of the Moon
musicCan 'The Endless River' carry on the tradition? See for yourself
Sport
New Zealand fly-half Aaron Cruden pictured in The Zookeeper's Son on a late-night drinking session
rugby
Arts and Entertainment
Worldwide ticket sales for The Lion King musical surpassed $6.2bn ($3.8bn) this summer
tvMusical is biggest grossing show or film in history
Voices
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Arts and Entertainment
Salmond told a Scottish television chat show in 2001that he would also sit in front of a mirror and say things like,
tvCelebrity Trekkies from Alex Salmond to Barack Obama
Life and Style
food + drink
News
Rob Merrick's Lobby Journalists were playing Ed Balls' Labour Party MPs. The match is an annual event which takes place ahead of the opening of the party conference
newsRob Merrick insistes 'Ed will be hurting much more than me'
News
A cabin crew member photographed the devastation after one flight
news
Life and Style
Carol O'Brien, whose son Rob suffered many years of depression
healthOne mother's story of how London charity Maytree helped her son with his depression
Life and Style
The Google Doodle celebrating the start of the first day of autumn, 2014.
tech
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Pharmaceutical Computer System Validation Specialist

    £300 - £350 Per Day: Clearwater People Solutions Ltd: Pharmaceutical Computer ...

    High Level Teaching Assistant (HTLA)

    £70 - £90 per day: Randstad Education Birmingham: Higher Level Teaching Assist...

    Teaching Assistant

    £50 - £80 per day: Randstad Education Birmingham: Randstad Education is the UK...

    Senior Java Developer - API's / Webservices - XML, XSLT

    £400 - £450 Per Day: Clearwater People Solutions Ltd: Our client is currently ...

    Day In a Page

    Secret politics of the weekly shop

    The politics of the weekly shop

    New app reveals political leanings of food companies
    Beam me up, Scottie!

    Beam me up, Scottie!

    Celebrity Trekkies from Alex Salmond to Barack Obama
    Beware Wet Paint: The ICA's latest ambitious exhibition

    Beware Wet Paint

    The ICA's latest ambitious exhibition
    Pink Floyd have produced some of rock's greatest ever album covers

    Pink Floyd have produced some of rock's greatest ever album covers

    Can 'The Endless River' carry on the tradition?
    Sanctuary for the suicidal

    Sanctuary for the suicidal

    One mother's story of how London charity Maytree helped her son with his depression
    A roller-coaster tale from the 'voice of a generation'

    Not That Kind of Girl:

    A roller-coaster tale from 'voice of a generation' Lena Dunham
    London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

    London is not bedlam or a cradle of vice

    In fact it, as much as anywhere, deserves independence
    Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

    Vivienne Westwood 'didn’t want' relationship with McLaren

    Designer 'felt pressured' into going out with Sex Pistols manager
    Jourdan Dunn: Model mother

    Model mother

    Jordan Dunn became one of the best-paid models in the world
    Apple still coolest brand – despite U2 PR disaster

    Apple still the coolest brand

    Despite PR disaster of free U2 album
    Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

    Despite the result, this is the end of the status quo

    Boyd Tonkin on the fall-out from the Scottish referendum
    Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

    Manolo Blahnik: Flats, Englishness, and Mary Beard

    The shoe designer who has been dubbed 'the patron saint of the stiletto'
    The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

    Scrambled eggs and LSD

    Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
    'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

    'Normcore': Blending in is the new standing out

    Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
    Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

    New leading ladies of dance fight back

    How female vocalists are now writing their own hits